Clinical Trials Logo

Epidermal Nevus Syndrome clinical trials

View clinical trials related to Epidermal Nevus Syndrome.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03993821 Active, not recruiting - Clinical trials for Epidermal Nevus Syndrome

Burosumab for CSHS

Start date: July 1, 2019
Phase: Early Phase 1
Study type: Interventional

Burosumab (also known as the drug, Crysvita®) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23), leading to an increase in serum phosphorus levels. This drug is already approved for use in patients with X-linked hypophosphatemia (XLH), but not for Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS). It is hypothesized that burosumab may provide clinical benefit to a patient with CSHS due to the common underlying feature in this patient and in patients with XLH - abnormally elevated FGF23 in the context of low age -adjusted serum phosphorous levels.